Endo International PLC (ENDP)

ENDP (NASDAQ:Drugs) EQUITY
$15.44
pos +0.28
+1.80%
Today's Range: 14.78 - 15.61 | ENDP Avg Daily Volume: 9,594,600
Last Update: 05/24/16 - 3:59 PM EDT
Volume: 6,221,404
YTD Performance: -75.25%
Open: $15.33
Previous Close: $15.16
52 Week Range: $12.56 - $88.54
Oustanding Shares: 222,661,344
Market Cap: 3,437,891,151
6-Month Chart
TheStreet Ratings Grade for ENDP
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 6 6 7
Moderate Buy 1 1 1 0
Hold 10 8 8 7
Moderate Sell 0 0 0 0
Strong Sell 1 0 0 0
Mean Rec. 2.47 2.13 2.13 2.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 4.54
Price Earnings Comparisons:
ENDP Sector Avg. S&P 500
4.54 0.00 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-69.82% -82.15% -55.79%
GROWTH 12 Mo 3 Yr CAGR
Revenue 13.60 0.10 0.03
Net Income 0.00 -0.60 0.00
EPS 0.00 0.20 0.00
Earnings for ENDP:
EBITDA 1.01B
Revenue 3.27B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $0.92 $1.16 $4.59 $5.23
Number of Analysts 10 10 11 12
High Estimate $1.36 $1.52 $4.66 $6.75
Low Estimate $0.72 $0.94 $4.51 $4.55
Prior Year $1.08 $1.02 $4.87 $4.59
Growth Rate (Year over Year) -14.91% 13.33% -5.81% 14.03%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Despite an earnings beat and upbeat outlook, its stock has suffered with other drug makers.
Bearish
May 06, 2016 | 7:42 AM EDT
ENDP was downgraded from Outperform to Sector Perform, RBC Capital said. $26 price target. Turnaround is going to take longer than expe...
The specialty pharmaceutical company gave investors a lot of news to digest -- and they fled.
the Sale of ASTORA Women's Health could bode well for the speciality pharma, as legal woes persist.
Mylan and Endo International look like bargains at current prices.
These biotech/pharma picks could give you a very happy new year.
The company cleared an important hurdle last month.
Bearish
Oct 26, 2015 | 7:40 AM EDT
ENDP was removed from the Conviction Buy list, according to Goldman Sachs. $84 price target. Company is leveraged to sector headwinds.&...
Bearish
Sep 01, 2015 | 6:43 AM EDT
ENDP was downgraded from Overweight to Equal-weight, Morgan Stanley said. $85 price target. Company has limited long-term growth visibi...
Bullish
Jul 17, 2015 | 7:11 AM EDT
ENDP was upgraded from Outperform to Top Pick, RBC Capital said. $107 price target. Company is attractively valued and consensus number...

Columnist Conversations

We knew what the trading world was looking at in recent weeks.  It was the famous head and shoulders top in t...
I've already posted this on twitter.  This is just a reminder that even though AAPL is rallying off the WEEKL...
Under Armour (UA) is getting lots of press today after signing "The largest revenue contract in NCAA history"....
FIBOCALL: XLF- Are you a BUYER today? The XLF is flirting with the 100 Week Moving Average @ 23.59 today. The ...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.